Covaxin shows 50% effectiveness against symptomatic COVID-19 in real-world assessment: Lancet study

The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3cJGRhG
via IFTTT